BNOX Bionomics Limited Stock Quote

BNOX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.16	Insider Own	-	Shs Outstand	7.28M	Perf Week	8.40%
Market Cap	51.65M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	4.74M	Perf Month	-19.32%
Income	-	PEG	-	EPS next Q	-	Inst Own	17.10%	Short Float	0.01%	Perf Quarter	-43.15%
Sales	0.49M	P/S	104.91	EPS this Y	-	Inst Trans	-	Short Ratio	0.20	Perf Half Y	-
Book/sh	0.94	P/B	7.55	EPS next Y	-	ROA	-	Target Price	0.92	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	5.70 - 22.00	Perf YTD	-43.43%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-67.73%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	24.56%	ATR	0.69
Employees	-	Current Ratio	-	Sales Q/Q	-72.00%	Oper. Margin	-	RSI (14)	42.88	Volatility	6.80% 5.12%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.00	Prev Close	7.10
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	2.97K	Price	7.10
Recom	-	SMA20	-7.44%	SMA50	-19.87%	SMA200	-30.79%	Volume	0	Change	0.00%

Jan-10-22

Initiated

H.C. Wainwright

Buy

$54

Jan-10-22

Initiated

Evercore ISI

Outperform

$17

Jan-10-22

Initiated

Cantor Fitzgerald

Overweight

$52

Jan-10-22

Initiated

Berenberg

Buy

$21

Jun-27-22 06:00AM	Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference GlobeNewswire
Jun-24-22 07:44AM	Fewer Investors Than Expected Jumping On Maxim Power Corp. (TSE:MXG) Simply Wall St.
Jun-13-22 04:30PM	Bionomics Investor Webinar GlobeNewswire -14.02%
May-16-22 06:00AM	Bionomics Limited to Participate in Upcoming Investor Conferences GlobeNewswire
May-10-22 08:00AM	Novamind to Host Bionomics PREVAIL Trial for Acute Treatment of Social Anxiety Disorder ACCESSWIRE
Feb-23-22 09:00PM	Bionomics' Half-Year Report GlobeNewswire
Jan-14-22 07:06AM	Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022 PR Newswire
Jan-12-22 06:00AM	Bionomics Limited participated in the H.C Wainwright BioConnect Conference PR Newswire
Jan-05-22 05:58PM	Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States PR Newswire
Jan-03-22 06:00AM	Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder PR Newswire
Dec-16-21 06:00AM	Bionomics Limited Announces Pricing of Initial Public Offering in the United States PR Newswire

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience